NGLY1 Deficiency – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036

NGLY1 Deficiency Market Outlook

Thelansis’s “NGLY1 Deficiency Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential NGLY1 Deficiency treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

NGLY1 Deficiency Overview

NGLY1 deficiency is a devastating, ultra-rare autosomal recessive congenital disorder of deglycosylation (CDDG) caused by biallelic loss-of-function mutations in the NGLY1 gene. This gene encodes N-glycanase 1, a critical cytosolic enzyme responsible for cleaving N-linked glycans from misfolded glycoproteins prior to their destruction by the proteasome. The fundamental absence of this enzyme critically cripples the endoplasmic reticulum-associated degradation (ERAD) pathway, driving the toxic intracellular accumulation of misfolded proteins and elevating the defining diagnostic biomarker, GlcNAc-Asn (GNA). Clinically, the disease manifests with a highly distinct tetrad of severe global developmental delay, a progressive hyperkinetic movement disorder, transient hepatic transaminase elevations, and the hallmark ocular symptom of (hypo)alacrima (reduced or absent tears). While historical management was strictly palliative—relying entirely on supportive physical and occupational therapies alongside aggressive, symptom-directed care—the therapeutic landscape is currently undergoing a monumental transformation. As of March 2026, the clinical focus has shifted entirely toward definitive genetic correction, spearheaded by the recent FDA Regenerative Medicine Advanced Therapy (RMAT) designation of GS-100. This groundbreaking, investigational AAV9-mediated gene replacement therapy, administered directly via intracerebroventricular (ICV) injection, targets the absolute root cause of the condition and represents the first viable pipeline strategy to halt neurologic progression and dramatically alter the natural history of this profound disorder.

 

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025–2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

Read more: NGLY1 Deficiency – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036